new patent clear runway alopecia program
reiter market outperform rate increas risk-adjust
dcf-deriv price target
new patent significantli prolong revenu tail alopecia
new composit matter patent provid compound
protect gener competit least decis
support view drug potenti best class
patent disput remain limbo believ worst
scenario would small royalti mo pt benjamin
life patent model expir result
adjust model increas outer-year revenu
rais price target
think repres best-in-class opportun could
garner opportun alopecia areata given size unmet need
competit landscap look phase start year
conserv extend outer-year revenu
reflect new price target
 patent trial appeal board ptab grant concert notic
allow patent cover pharmaceut composit
method treat alopecia areata importantli patent
protect compound gener substitut cover
clinic dose show impress efficaci phase see
note
note patent separ patent
success challeng ptab determin cnce claim
composit matter deuter form inci ruxolitinib
patent last april see note concert appeal
rule manag state may take year play meantim
believ news today add support notion best-
in-class compound alopecia areata
market opportun
alreadi incorpor royalti model
given today event increas length revenu tail
year year exclus model adjust result
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
price target increas believ justifi
see potenti market opportun base unmet
need alopecia areata possibl competit advantag
development-stag asset nc
nc moreov work addit ip outsid newli assign
patent could help shore exclus
next step
next step program initi phase studi look
forward hear detail trial design later year
compani come agreement fda two program
phase think regulatori path rel clear like
includ two phase studi anticip studi start year
project launch follow launch
thesi
today valuat reflect littl valu consid today
news think share meaning under-valued recommend
share compani continu advanc proprietari deuter pipelin
alopecia areata schizophrenia two larg
address patient popul estim combin repres
peak sale
discount inc ex-u inc ex-u oper incom adjust net incom year discounting- valu l-t debt- valu valu per programpostermin dilut assumptionstot inc inc
clinical-stag biopharmaceut compani seek discov develop novel small molecul drug
improv exist drug clinic candid via deuterium substitut deuterium substitut lead drug superior
pharmacokinet metabol properti improv clinic safeti toler and/or efficaci deuter analog approv drug may also
abl benefit expedit pathway fda approv firm current number clinical-stag product candid includ
alopecia areata neurolog psychiatr disord collabor
lastli compani recent nomin novel develop candid potenti treatment neg symptom associ
schizophrenia known deuter form d-serin
clinic risk product undergo clinic trial may seriou safeti concern lack efficaci fail demonstr statist signific
would preclud continu clinic develop eventu commerci compani deuter chemic
entiti dce platform technolog proven like downsid share price risk viabil compani
addit yet demonstr abil success conduct large-scal pivot clinic trial obtain market approv
manufactur commerci scale product conduct sale market activ necessari success product commerci
collabor risk depend upon collabor third parti develop commerci
compani product candid expect continu futur cnce busi model reli make use dce platform
partner compani improv exist drug candid cnce prospect respect
product candid depend signific part upon success collabor
manufactur risk clinical-stag biopharmaceut compani appli extens knowledg deuterium chemistri discov
develop novel small molecul drug limit sourc deuterium collabor expos number
risk uncertainti associ compani deuterium suppli particular manufactur process mani compani
drug candid project requir larg quantiti deuterium late-stag clinic trial commerci consequ
advers impact cnce abil obtain deuterium oxid could signific impact compani abil develop
commerci product candid similarli cnce collabor also need obtain suppli deuterium subject risk
requir connect sourc deuterium similar one compani face
financi risk current deriv revenu research develop fund licens collabor
agreement compani yet profit histori oper loss expect continu near futur develop
pharmaceut product includ conduct preclin studi clinic trial time-consum expens uncertain process
take year complet must continu financ clinic trial complet may unabl secur addit
fund forc delay reduc elimin product develop program commerci effort compani incur
signific loss sinc incept expect loss occur next sever year
regulatori risk collabor may instanc abl secur clearanc fda compar foreign
regulatori author use expedit develop pathway unabl obtain clearanc collabor may
requir conduct addit preclin studi clinic trial beyond contempl could increas expens obtain
delay receipt necessari market approv
research analyst prepar report does/do herebi certifi view present report accord my/our
person view secur issuer discuss report mandat sec regul ac part my/our compens
directli indirectli relat specif view recommend express herein certif made
oblig set forth sec regul ac person entiti may use purpos certif made
base my/our analysi date report public i/w assum oblig updat certif reflect fact
circumst event may subsequ come my/our attent sign liisa bayko jonathan wolleben neil panchal
jmp secur current make market secur inc incyt corpor
jmp secur expect receiv intend seek compens invest bank servic inc
incyt corpor next month
market outperform mo jmp secur expect stock price outperform relev market indic next month
market perform mp jmp secur expect stock price perform line relev market indic next month
market under-perform mu jmp secur expect stock price under-perform relev market indic next month
jmp secur research rate invest bank servic januari
servic
co
stock price chart rate price chang
note first annot denot initi coverag year whichev shorter target price list target price n/a
accord finra rule chart reflect price rang chang rate price target end
recent calendar quarter action reflect note annot stock price chart jmp secur
jmp secur llc firm compens research analyst like firm employe base firm profit includ
revenu firm institut sale trade invest bank depart well qualiti servic activ
perform intend benefit firm institut client data prepar jmp secur llc inform
purpos base inform avail public sourc believ reliabl guarante
accuraci complet opinion project express herein reflect judgment date subject chang
without notic data neither intend consid offer sell solicit basi contract
purchas secur financi product jmp secur llc affili jmp group llc harvest capit strategi llc
respect partner director offic associ may long short posit may act market maker may
purchas sell posit secur mention herein jmp secur llc affili may perform perform seek
perform invest bank advisori servic may act manag co-manag public offer secur
compani mention herein reader assum jmp secur llc solicit busi compani cover
report member sale trade depart provid oral and/or written market opinion trade strategi client
reflect person opinion stock subject firm research report research analyst discuss trade
strategi client sometim reflect short-term expect price secur subject research report
trade strategi distinct analyst fundament rate stock base upon analyst view compar
stock coverag relev time period copyright right reserv jmp secur llc jmp secur
llc member finra sipc
director research
director equiti
director sale trade
